168 related articles for article (PubMed ID: 8491056)
1. Clinical pharmacokinetics of idarubicin.
Robert J
Clin Pharmacokinet; 1993 Apr; 24(4):275-88. PubMed ID: 8491056
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model.
Berg SL; Reid J; Godwin K; Murry DJ; Poplack DG; Balis FM; Ames MM
J Pediatr Hematol Oncol; 1999; 21(1):26-30. PubMed ID: 10029808
[TBL] [Abstract][Full Text] [Related]
3. [A pharmacokinetic study of idarubicin hydrochloride, a new anthracycline anti-tumor drug, in patients with acute leukemia. Idarubicin Study Group].
Fujita H; Ogawa M; Masaoka T; Yamada K; Kimura K
Gan To Kagaku Ryoho; 1992 Jun; 19(6):791-8. PubMed ID: 1605655
[TBL] [Abstract][Full Text] [Related]
4. Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients: a Childrens Cancer Study Group report.
Reid JM; Pendergrass TW; Krailo MD; Hammond GD; Ames MM
Cancer Res; 1990 Oct; 50(20):6525-8. PubMed ID: 2208112
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of idarubicin after oral administration in elderly leukemic patients.
Robert J; Rigal-Huguet F; Huet S; Pris J; Hurteloup P
Leukemia; 1990 Mar; 4(3):227-9. PubMed ID: 2179640
[TBL] [Abstract][Full Text] [Related]
6. Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve.
Schleyer E; Kühn S; Rührs H; Unterhalt M; Kaufmann CC; Kern W; Braess J; Sträubel G; Hiddemann W
Leukemia; 1996 Apr; 10(4):707-12. PubMed ID: 8618451
[TBL] [Abstract][Full Text] [Related]
7. Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve.
Schleyer E; Kühn S; Rührs H; Unterhalt M; Kaufmann CC; Kern W; Braess J; Sträubel G; Hiddemann W
Leukemia; 1997 Dec; 11 Suppl 5():S15-21. PubMed ID: 9436933
[TBL] [Abstract][Full Text] [Related]
8. A phase I study of idarubicin hydrochloride in patients with acute leukemia. The Idarubicin Study Group of Japan.
Tamura K
Semin Hematol; 1996 Oct; 33(4 Suppl 3):2-11. PubMed ID: 8916310
[TBL] [Abstract][Full Text] [Related]
9. Comparative pharmacokinetic study of idarubicin and daunorubicin in leukemia patients.
Robert J; Rigal-Huguet F; Hurteloup P
Hematol Oncol; 1992; 10(2):111-6. PubMed ID: 1592361
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and tissue distribution of idarubicin and its active metabolite idarubicinol in the rabbit.
Looby M; Linke R; Weiss M
Cancer Chemother Pharmacol; 1997; 39(6):554-6. PubMed ID: 9118470
[TBL] [Abstract][Full Text] [Related]
11. Bioavailability and pharmacology of oral idarubicin.
Stewart DJ; Grewaal D; Green RM; Verma S; Maroun JA; Redmond D; Robillard L; Gupta S
Cancer Chemother Pharmacol; 1991; 27(4):308-14. PubMed ID: 1998987
[TBL] [Abstract][Full Text] [Related]
12. High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study.
Tedeschi A; Montillo M; Strocchi E; Cafro AM; Tresoldi E; Intropido L; Nichelatti M; Marbello L; Baratè C; Camaggi CM; Morra E
Cancer Chemother Pharmacol; 2007 May; 59(6):771-9. PubMed ID: 17256136
[TBL] [Abstract][Full Text] [Related]
13. Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture.
Kuffel MJ; Reid JM; Ames MM
Cancer Chemother Pharmacol; 1992; 30(1):51-7. PubMed ID: 1586980
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of idarubicin after daily intravenous administration in leukemic patients.
Robert J; Rigal-Huguet F; Harousseau JL; Pris J; Huet S; Reiffers J; Hurteloup P; Tamassia V
Leuk Res; 1987; 11(11):961-4. PubMed ID: 3480399
[TBL] [Abstract][Full Text] [Related]
15. Comparison of idarubicin and daunorubicin and their main metabolites regarding intracellular uptake and effect on sensitive and multidrug-resistant HL60 cells.
Tidefelt U; Prenkert M; Paul C
Cancer Chemother Pharmacol; 1996; 38(5):476-80. PubMed ID: 8765443
[TBL] [Abstract][Full Text] [Related]
16. Plasma pharmacokinetics of idarubicin and its 13-dihydro metabolite--a comparison of bolus versus 2 h infusion during a 3 day course.
Eksborg S; Björkholm M; Hast R; Fagerlund E
Anticancer Drugs; 1997 Jan; 8(1):42-7. PubMed ID: 9147610
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and tissue distribution of idarubicin-loaded solid lipid nanoparticles after duodenal administration to rats.
Zara GP; Bargoni A; Cavalli R; Fundarò A; Vighetto D; Gasco MR
J Pharm Sci; 2002 May; 91(5):1324-33. PubMed ID: 11977108
[TBL] [Abstract][Full Text] [Related]
18. [Pharmacokinetics of new anthracyclines].
Robert J
Bull Cancer; 1988; 75(2):167-74. PubMed ID: 3282579
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the intracellular pharmacokinetics of daunorubicin and idarubicin in patients with acute leukemia.
Tidefelt U; Sundman-Engberg B; Paul C
Leuk Res; 1994 Apr; 18(4):293-7. PubMed ID: 8170171
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of oral idarubicin in breast cancer patients with reference to antitumor activity and side effects.
Elbaek K; Ebbehøj E; Jakobsen A; Juul P; Rasmussen SN; Bastholt L; Dalmark M; Steiness E
Clin Pharmacol Ther; 1989 Jun; 45(6):627-34. PubMed ID: 2731405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
